We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Grant to Pfizer Sample Clauses

Grant to Pfizer. Rigel hereby grants to Pfizer an exclusive, world-wide license, including the right to grant sublicenses, to research, manufacture, use, sell, offer for sale and import Licensed Products under Rigel's interest in the Product Patent Rights and the Molecular Targets.
Sample 1Sample 2Sample 3See All (5)
Grant to Pfizer. Esperion hereby grants to Pfizer: (a) a worldwide, exclusive, fully paid-up license (with right to sublicense) under all Intellectual Property Controlled by Esperion or its Affiliates as of the Effective Date (including the Esperion Transferred IP but excluding the Pfizer Transferred IP) that was practiced by or on behalf of Pfizer or any of its Affiliates prior to or on the Effective Date in the conduct of the Pfizer Programs (the “Exclusive Esperion Licensed IP”), to develop, manufacture, have manufactured, sell, offer for sale, import and use the compounds or pharmaceutical products comprising compounds that arise out of the Pfizer Programs. (b) Without limiting the generality of the foregoing clause (a), a worldwide, exclusive, fully paid-up sublicense to that Intellectual Property related to the ETC-642 Pfizer Program as set forth in Schedule A, attached hereto, to develop, manufacture, have manufactured, sell, offer for sale, import and use the compounds or pharmaceutical products comprising compounds that arise out of the Pfizer Programs. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. (c) a worldwide, non-exclusive, fully-paid up license (with right to sublicense to Affiliates without Esperion’s consent, and to Third Parties only with Esperion’s consent, not to be unreasonably withheld) to practice and use, in each case solely for research purposes, all Intellectual Property Controlled by Esperion as of the Effective Date (including the Esperion Transferred IP), including all such rights that directly relate to the ApoA-1 Target (such Intellectual Property, together with the Exclusive Esperion Licensed IP, the “Esperion Licensed IP”). Notwithstanding the foregoing, such license granted under this Section 3.1(c) shall not include the right for Pfizer, or any of its Affiliates and sublicensees, to make, have made, research, develop, use or test any of the compounds now comprising the Esperion Program or any compounds claimed under the same Patents that claim or cover the composition of matter of, or the method of making or using, ETC-1002 (the “Restricted Compounds”). Notwithstanding the foregoing restriction, Pfizer may use such Restricted Compounds as a reference standard onl...
Sample 1Sample 2
Grant to Pfizer. 2.1.1. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer an exclusive (even as to Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Commercialize the Licensed Compounds and Licensed Products in the Field in the Territory. 2.1.2. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer a co-exclusive (with Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Develop the Licensed Compounds and Licensed Products in the Field in the Territory, including to Develop the Licensed Products in order to perform the Assumed Development Activities in the Territory. 2.1.3. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer a co-exclusive (with Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Manufacture the Licensed Compounds and Licensed Products in the Field in the Territory.
Sample 1
Grant to Pfizer. Subject to the terms and conditions of this Agreement, XOMA hereby grants to PFIZER a non-exclusive, non-transferable, worldwide license, solely within the Field, under the Patent Rights, without the right to grant sublicenses, on its own behalf to conduct Research and Development and to make, have made, use, sell, have sold, offer to sell, import and export Licensed Products, including without limitation Licensed Products arising out of a PFIZER Display System. The license granted pursuant to this Section 2.1 shall be [*] retroactive.
Sample 1
Grant to Pfizer. 14.1.1. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer an exclusive (even as to BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Commercialize the Licensed Compounds and Licensed Products in the Field in the Territory. 14.1.2. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer a co-exclusive (with BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Develop the Licensed Compounds and Licensed Products in the Field in the Territory, including to Develop the Licensed Products in order to perform the Assumed Development Activities in the Territory. 14.1.3. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer co-exclusive (with BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Manufacture the Licensed Compounds and Licensed Products in the Field in the Territory.
Sample 1
Grant to Pfizer 
Sample 1Sample 2

Related to Grant to Pfizer

  • Date of Grant The date that the Option is granted (the “Date of Grant”) is set forth above.

  • Grant Date The Grant Date of the Option hereby granted is .

  • Agreement to Purchase The Seller agrees to sell, and the Purchaser agrees to purchase, on a servicing released basis, the Mortgage Loans identified on the schedule (the "Mortgage Loan Schedule") annexed hereto as Exhibit 1, as such schedule may be amended to reflect the actual Mortgage Loans accepted by the Purchaser pursuant to the terms hereof. The Cut-Off Date with respect to each Mortgage Loan is such Mortgage Loan's Due Date in the month of August 2004. The Mortgage Loans will have an aggregate principal balance as of the close of business on the Cut-Off Date, after giving effect to any payments due on or before such date, whether or not received, of $85,459,192. The sale of the Mortgage Loans shall take place on August 24, 2004 or such other date as shall be mutually acceptable to the parties hereto (the "Closing Date"). The purchase price to be paid by the Purchaser for the Mortgage Loans shall equal the amount set forth as such purchase price on Exhibit 3 hereto. The purchase price shall be paid to the Seller by wire transfer in immediately available funds on the Closing Date. On the Closing Date, the Purchaser will assign to the Trustee pursuant to the Pooling and Servicing Agreement all of its right, title and interest in and to the Mortgage Loans and its rights under this Agreement (to the extent set forth in Section 14), and the Trustee shall succeed to such right, title and interest in and to the Mortgage Loans and the Purchaser's rights under this Agreement (to the extent set forth in Section 14).

  • Grant of Stock Option The Company hereby grants the Optionee an Option to purchase shares of Common Stock, subject to the following terms and conditions and subject to the provisions of the Plan. The Plan is hereby incorporated herein by reference as though set forth herein in its entirety. The Option is not intended to be and shall not be qualified as an “incentive stock option” under Section 422 of the Code.

  • Payment of Grant On or before the 30th day following the close of each calendar quarter that falls within the Term, Grantee shall submit an invoice to Project Monitor detailing all Project Account costs for the prior three calendar months, to the extent that the prior three calendar months fall within the Term, along with all supporting documentation and support therefor, as described in Paragraph 7 of this Grant Contract. Costs contained in untimely, unsupported, or otherwise incomplete invoices shall be deemed Unauthorized Costs, for which Sponsor shall not be liable, directly or indirectly. Grantee shall submit invoices to the Human Services Office via email on the following dates: For the period of July – September, due on or before October 31, 2024 For the period of October – December, dues on or before January 31, 2025 For the period of January – March, due on or before April 30, 2025 For the period of April – June, due on or before June 30, 2025 Xxxxxxx’s invoices submitted hereunder shall be handled as all other claims against the Sponsor. No payment shall be made for Unauthorized Costs. The Sponsor shall authorize payment for Xxxxxxx’s invoices only after Project Monitor assures the Sponsor in writing that Services rendered by Grantee prior to the date of making the claim were performed in accordance with the Grant Contract, and that all costs conform to the Project Budget. Such assurance shall include the submission of all supporting documentation and support for costs as described in Paragraph 7 of this Grant Contract.

  • Stock Option Grant Subject to the provisions set forth herein and the terms and conditions of the Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

  • Option Grant Subject to the provisions set forth herein the Company hereby grants to the Optionee, as a matter of separate agreement and not in lieu of compensation for services rendered to the Company, the right and option to purchase up to an aggregate of 250,000 shares of its Common Stock (the "Option"). The Option is intended to be a Non-Statutory Stock Option that does not qualify as an Incentive Stock Option under Section 422 of the Internal Revenue Code of 1986, as amended.

  • Grant Terms The funding for this Agreement is provided in full or in part by a Federal or State Grant to the City. As part of the terms of receiving the funds, the City is required to incorporate some of the terms into this Agreement. The incorporated terms may be found in Appendix [choose C/D/E etc.], “Grant Terms.” To the extent that any Grant Term is inconsistent with any other provisions of this Agreement such that Contractor is unable to comply with both the Grant Term and the other provision(s), the Grant Term shall apply.

  • Award Date <Award Date>

  • Grant of RSUs The Company hereby grants to the Grantee the Award of RSUs, as set forth in the Award letter. An RSU is the right, subject to the terms and conditions of the Plan and this Agreement, to receive a distribution of a share of Common Stock for each RSU as described in Section 6 of this Agreement.

Most Referenced Clauses

Most Referenced Definitions